The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues
DSpace/Manakin Repository
- DASH Home
- Harvard Law School
- HLS Student Papers
- View Item
The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues
| Title: | The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues |
| Author: | Kaufman, Robert |
| Citation: | The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues (2004 Third Year Paper) |
| Full Text & Related Files: |
Kaufman.pdf (238.4Kb; PDF) 
Kaufman.rtf (245.6Kb; RTF file) 
Kaufman.html (250.9Kb; HTML)
|
| Abstract: | The regulation off-label drugs is a complicated and controversial area of the law. Regulators must protect patients’ safety without interfering with physicians’ practice of medicine or manufacturers’ First Amendment rights. The recent Neurontin decisions, which apply the doctrine of false claims to prescription drug regulation, only adds additional complexity. This paper explores the federal government’s attempts to regulate the promotion of off-label drugs. It discussed the advantages and disadvantages of off-label marketing, the current regulatory environment, and the implications of the Neurontin lawsuit. |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:8963868 |
This item appears in the following Collection(s)
-
HLS Student Papers [558]
HLS Student Papers
Contact administrator regarding this item (to report mistakes or request changes)
